3-Acetoxy-4-nitro-benzoesaeure | 51257-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Acetoxy-4-nitro-benzoesaeure
• 英文别名: 3-Acetoxy-4-Nitrobenzoic Acid；3-acetyloxy-4-nitrobenzoic acid
• CAS: 51257-24-0
• 化学式: C₉H₇NO₆
• 分子量: 225.158
• InChiKey: CXXFEUYSCNJQFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-Acetoxy-4-nitro-benzoesaeure 在 吡啶 、 N-甲基吡咯烷酮 、 氢氧化钾 、 氯化亚砜 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 0.92h， 生成 1-<5-(tert-Butoxycarbonyl)-2-nitrophenoxy>-2-(5-methyl-2-nitrophenoxy)ethane
  参考文献：
  名称：

  Biologically useful chelators that take up calcium(2+) upon illumination

  摘要：

  DOI：

  10.1021/ja00202a042
• 作为产物：
  描述：

  3-羟基-4-硝基苯甲酸 在 吡啶 作用下， 以 乙酸酐 为溶剂， 生成 3-Acetoxy-4-nitro-benzoesaeure
  参考文献：
  名称：

  Amino-benzoic acids and derivatives, and methods of use

  摘要：

  本发明涉及用于抑制非酶促交联（蛋白质老化）的化合物、组合物和方法。因此，公开了一种组合物，该组合物包括能够通过与由目标蛋白的初始糖基化形成的早期糖基化产物的羰基基团反应，从而抑制目标蛋白的高级糖基化终产物形成的剂。该方法包括将目标蛋白与该组合物接触。该发明预见了工业和治疗方法的应用，因为食品腐败和动物蛋白质老化可以被处理。

  公开号：

  US05514676A1

文献信息

• Substituted bicyclic heteroaryl compounds and their use as integrin antagonists
  申请人：——

  公开号：US20020173506A1

  公开（公告）日：2002-11-21

  The invention is directed to physiologically active compounds of general formula (I): R 1 Z 1 —Het—L 1 —Ar 1 —L 2 —Y  (I) wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring containing at least one heteroatom selected from O, S or N; R 1 is optionally substituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; Z 1 represents a direct bond, an alkylene chain, NR 4 , O or S(O) n ; L 1 is an a —R 5 —R 6 — linkage where R 5 is alkylene, alkenylene or alkynylene and R 6 is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, —C(═Z 3 )—NR 4 —, —NR 4 —C(═Z 3 )—, —Z 3 —, —C(═O)—, —C(═NOR 4 )—, —NR 4 —, —NR 4 —C(═Z 3 )—NR 4 —, —SO 2 —NR 4 —, —NR 4 —SO 2 —, —O—C(═O)—, —C(═O)—O—, —NR 4 —C(═O)—O— or —O—C(═O)—NR 4 —; L 2 is a direct bond; an optionally substituted alkylene, alkenylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage; a —[C(═O)—N(R 9 )—C(R 4 )(R 10 )] p — linkage; a —Z 4 —R 11 — linkage; a —C(═O)—CH 2 —C(═O)— linkage; a —R 11 —Z 4 —R 11 — linkage; or a —L 3 —L 4 —L 5 — linkage; and Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

  该发明涉及一般式(I)的生理活性化合物： R1Z1—Het—L1—Ar1—L2—Y  (I) 其中，Het是一个可选择取代的、饱和的、部分饱和的或完全不饱和的含有至少一个来自O、S或N的杂原子的8到10成员的双环环；R1是可选择取代的芳基、杂环芳基、烷基、烯基、炔基、环烷基或杂环烷基；Z1代表直链键、烷基链、NR4、O或S(O)n；L1是一个a—R5—R6—连接，其中R5是烷基、烯基或炔基，R6是直链、环烷基、杂环烷基、芳基、杂芳基二烷基、—C(═Z3)—NR4—、—NR4—C(═Z3)—、—Z3—、—C(═O)—、—C(═NOR4)—、—NR4—、—NR4—C(═Z3)—NR4—、—SO2—NR4—、—NR4—SO2—、—O—C(═O)—、—C(═O)—O—、—NR4—C(═O)—O—或—O—C(═O)—NR4—；L2是一个直链；一个可选择取代的烷基、烯基、炔基、环烯基、环烷基、杂芳基二烷基、杂环烷基或芳基连接；一个—[C(═O)—N(R9)—C(R4)(R10)]p—连接；一个—Z4—R11—连接；一个—C(═O)—CH2—C(═O)—连接；一个—R11—Z4—R11—连接；或一个—L3—L4—L5—连接；Y是羧基或酸生物同位素；以及相应的N-氧化物，它们的前药；以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂化合物（例如水合物）。 这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4（α4β1）相互作用的能力。
• Methods for glycosylation inhibition using amino-benzoic acids and
  申请人：The Rockefeller University

  公开号：US05476849A1

  公开（公告）日：1995-12-19

  The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

  本发明涉及用于抑制非酶促交联（蛋白质老化）的化合物、组合物和方法。因此，公开了一种组合物，该组合物包括能够通过与由目标蛋白的初始糖基化形成的早期糖基化产物的羰基基团反应，从而抑制目标蛋白的高级糖基化终产物的形成的剂。所述方法包括将目标蛋白与该组合物接触。本发明的应用前景包括工业和医疗用途，因为食品腐败和动物蛋白质老化都可以得到治疗。
• Substituted bicyclic compounds
  申请人：——

  公开号：US20020137782A1

  公开（公告）日：2002-09-26

  The invention is directed to physiologically active compounds of formula (Ia): 1 wherein R 1 is optionally substituted aryl or optionally substituted heteroaryl; R 2 is hydrogen, halogen, lower alkyl or lower alkoxy; R 3 is alkylene, alkenylene or alkynylene; R 5 is hydrogen or lower alkyl; L 2 is optionally substituted alkylene or alkenylene; Y is carboxy; and Z 1 is NR 5 ; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

  该发明涉及式(Ia)的生理活性化合物： 其中R1是可选择取代的芳基或可选择取代的杂环芳基；R2是氢、卤素、低碳基或低烷氧基；R3是烷基、烯基或炔基；R5是氢或低碳基；L2是可选择取代的烷基或烯基；Y是羧基；Z1是NR5；以及相应的N-氧化物，它们的前药；以及这些化合物及其N-氧化物和前药的药学上可接受的盐和溶剂化合物（例如水合物）。 这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4（α4β1）相互作用的能力。
• Water Soluble Steroids with Catalytic Substituents II. Synthesis of 3β-(4(5)-Imidazolyl)-5α-androstane-11β, 17β,-diamine and Comparison of its Catalytic Properties with Those of 17β-(4(5)-Imidazolyl)-5α-androstane-3β, 11β-diamine
  作者：J. Peter Guthrie、Yasutsugu Ueda

  DOI：10.1139/v73-586

  日期：1973.12.1

  3β-(4(5)-Imidazolyl)-5α-androstane-11β,17β-diamine, 15, has been synthesized in a multistep process from adrenosterone, 2, starting with lithium ammonia reduction to give 11α,17β-dihydroxy-5α-androstan-3-one, 3, which was converted to its diacetate, 4. Ethynylation at the 3 keto group gave the ethynyl triol 5, purified as its11,17-diacetate 6. Acid catalyzed rearrangement of 6 gave 3-acetyl-5α-androst-2-ene-11α,17β-diol diacetate, 7. This was hydrogenated, and then subjected to base catalyzed hydrolysis and equilibration to give crystalline 3β-acetyl-5α-androstane-11α,17β-diol, 9, which was converted to 3β-acetoxyacetyl-5α-androstane-11α,17β-diol, 10, using lead tetraacetate. After hydrolysis to the triol, 11, the Weidenhagen reaction led to formation of 3β-imidazolyl-5α-androstane-11α,17β-diol, 12. Finally oxidation to the dione, 13, formation of the dioxime, 14, and hydrogénation give 15. As expected 15 is a better catalyst than 17β-(4(5)-imidazolyl-5α-androstane-3β,11β-diamine, 1, for the hydrolysis of aryl esters of acids with hydrophobic substituents, but the effect is small. With 1 there is a marked electrostatic rate enhancement or retardation when charged groups are present on the aryl esters; this effect is much smaller for 15.

  3β-(4(5)-咪唑基)-5α-雄烷-11β,17β-二胺，15，是从腺酮，2，经过多步合成的，首先进行锂氨还原得到11α,17β-二羟基-5α-雄甾-3-酮，3，然后转化为其二乙酸酯，4。在3酮基上进行乙炔基化得到乙炔三醇5，纯化为其11,17-二乙酸酯6。酸催化6的重排得到3-乙酰基-5α-雄烷-2-烯-11α,17β-二醇二乙酸酯，7。这经过氢化，然后经过碱催化水解和平衡得到结晶的3β-乙酰基-5α-雄烷-11α,17β-二醇，9，它被转化为3β-乙酰氧乙酰-5α-雄烷-11α,17β-二醇，10，使用四乙酸铅。水解为三醇后，11，魏登哈根反应导致形成3β-咪唑基-5α-雄烷-11α,17β-二醇，12。最后氧化为二酮，13，形成二肟，14，和氢化得到15。如预期的那样，15比17β-(4(5)-咪唑基-5α-雄烷-3β,11β-二胺，1，更好地催化含疏水取代基的芳基酯的水解，但效果很小。对于1，当芳基酯上存在带电基团时，会出现明显的静电速率增强或减缓；而对于15，这种效应要小得多。
• Guthrie,J.P.; Ueda,Y., Canadian Journal of Chemistry, 1976, vol. 54, p. 2745 - 2758
  作者：Guthrie,J.P.、Ueda,Y.

  DOI：——

  日期：——